As of 2026-05-20, the EV/EBITDA ratio of Prelude Therapeutics Inc (PRLD) is -6.78. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PRLD's latest enterprise value is 233.75 mil USD. PRLD's TTM EBITDA according to its financial statements is -34.47 mil USD. Dividing these 2 quantities gives us the above PRLD EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 15.3x | 14.4x |
| Forward P/E multiples | 14.5x - 19.5x | 17.0x |
| Fair Price | (7.35) - (7.79) | (8.03) |
| Upside | -272.2% - -282.4% | -288.1% |
| Date | EV/EBITDA |
| 2026-05-15 | -7.16 |
| 2026-05-14 | -7.15 |
| 2026-05-13 | -7.49 |
| 2026-05-12 | -7.46 |
| 2026-05-11 | -7.75 |
| 2026-05-08 | -7.86 |
| 2026-05-07 | -8.39 |
| 2026-05-06 | -7.82 |
| 2026-05-05 | -7.51 |
| 2026-05-04 | -7.64 |
| 2026-05-01 | -7.57 |
| 2026-04-30 | -8.54 |
| 2026-04-29 | -6.78 |
| 2026-04-28 | -7.00 |
| 2026-04-27 | -7.24 |
| 2026-04-24 | -7.57 |
| 2026-04-23 | -7.02 |
| 2026-04-22 | -6.85 |
| 2026-04-21 | -7.42 |
| 2026-04-20 | -7.22 |
| 2026-04-17 | -7.09 |
| 2026-04-16 | -7.07 |
| 2026-04-15 | -9.07 |
| 2026-04-14 | -7.02 |
| 2026-04-13 | -6.96 |
| 2026-04-10 | -6.43 |
| 2026-04-09 | -7.02 |
| 2026-04-08 | -6.69 |
| 2026-04-07 | -7.02 |
| 2026-04-06 | -5.70 |
| 2026-04-02 | -5.30 |
| 2026-04-01 | -5.28 |
| 2026-03-31 | -5.23 |
| 2026-03-30 | -4.59 |
| 2026-03-27 | -4.55 |
| 2026-03-26 | -4.90 |
| 2026-03-25 | -4.94 |
| 2026-03-24 | -4.68 |
| 2026-03-23 | -4.75 |
| 2026-03-20 | -4.44 |
| 2026-03-19 | -4.81 |
| 2026-03-18 | -4.68 |
| 2026-03-17 | -5.25 |
| 2026-03-16 | -5.12 |
| 2026-03-13 | -5.01 |
| 2026-03-12 | -5.14 |
| 2026-03-11 | -5.94 |
| 2026-03-10 | -5.56 |
| 2026-03-09 | -4.62 |
| 2026-03-06 | -4.88 |